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Abstract  
Objective: Diagnosing obstructive sleep apnea (OSA) usually involves high cost, patient 
inconvenience, and the need for examination at a specialized center. This study employed a 
portable, wearable, diagnostic device (WatchPAT) to investigate the prevalence of OSA in non-
obese Japanese patients with type 2 diabetes. 
Methods: Patients with type 2 diabetes were tested for OSA over one night using the WatchPAT. 
Logistic regression analysis was used to estimate the odds ratios (ORs) of risk factors for OSA 
in non-obese subjects. 
Results: A total of 200 eligible patients with type 2 diabetes were studied (64.5% men; aged 
60.1±13.6 years; BMI 26.3 ± 5.2 kg/m2). When OSA was defined as apnea-hypopnea index 
(AHI) ≥5/h, its prevalence was 80.5%. The prevalence of OSA in subjects with a BMI<20 
kg/m2, BMI≥20 and <25 kg/m2, BMI≥25 and <30 kg/m2, and BMI≥30 kg/m2 was 38.9%, 
73.5%, 86.5%, and 97.5%, respectively. The severity of OSA increased in proportion to BMI, 
especially when the BMI was higher than 25 kg/m2. The prevalence of OSA was also high 
(66.3%) in normal-weight subjects (BMI < 25 kg/m2). Furthermore, the serum triglyceride 
level (OR: 1.01; 95% CI: 1.00–1.02, P=0.042) was significantly related to OSA. 
Conclusion: A high prevalence of OSA was observed in this non-obese population of Japanese 
patients with type 2 diabetes. The triglyceride level was associated with OSA among non-obese 
patients.  
Keywords: Diabetes Mellitus Type 2; Obesity; Diabetes Complications 
Running title: Sleep apnea and diabetes 
Introduction 
Obstructive sleep apnea (OSA) is a disorder characterized by frequent episodes of collapse 
of the upper airway tissues during sleep, leading to sleep fragmentation. OSA is associated with 
an increased incidence of cardiovascular disease, excessive daytime sleepiness, and cognitive 
dysfunction (Sanchez et al, 2009).  
OSA has been suggested to have an extremely high prevalence among patients with type 2 
diabetes (T2D) (Meslier et al, 2003), and the International Diabetes Federation Taskforce on 
Epidemiology and Prevention strongly recommends screening every patient with type 2 
diabetes for OSA (Shaw et al, 2008). The reported prevalence of OSA in patients with T2D 
ranges from 53.9% to as high as 86.6% (OSA was defined as apnea-hypopnea index (AHI) ≥5 
events/h) (Foster et al, 2009; Lam et al, 2010; Zhang et al, 2015; Zhang et al, 2016). The 
prevalence of sleep-disordered breathing among Japanese patients with type 2 diabetes has 
been reported to be 77.5% (Kashine et al, 2010) and 45.4% (Furukawa et al, 2013). This wide 
variation may be due to differences in patient populations, the body mass index (BMI), and 
measurement of sleep apnea. Moreover, an association between the presence or severity of 
OSA and the worsening of Type 2 diabetes has been reported (Aronsohn et al, 2010).  
Obesity is associated with both OSA and T2D. Many studies have shown that a high BMI is 
related to an increased prevalence of OSA (Yamagishi et al, 2010), especially in Caucasians 
(Coltman et al, 2000; Leong et al, 2013). The prevalence of sleep apnea among Japanese 
patients without T2D with normal and overweight BMI (BMI ≥25 kg/m2) was reported as 
15.3% and 26.4%, respectively, on the basis of a respiratory disturbance index of over 15 events 
per h (Yamagishi et al, 2010). However, OSA has little association with obesity in Asian 
populations (Kono et al, 2007). Moreover, the severity distribution of OSA is similar among 
Asians and Caucasians, even though Asians have a lower BMI (Kang et al, 2014), which 
suggests that the prevalence and severity of OSA may be high among non-obese Asians. 
Despite this possibility, surprisingly little is known about OSA in non-obese Japanese patients 
(BMI<25 kg/m2) with T2D. 
Polysomnography is the gold standard for assessing sleep-disordered breathing, but it has 
some demerits such as a high cost, the burden imposed on patients, and the need for 
examination at a specialized center. Recently, some simpler screening devices have been 
reported to achieve high diagnostic accuracy for OSA (Susan et al, 2008). Among these devices, 
the WatchPAT (Itamar Medical, Cesarea, Israel) has shown reliable and valid diagnostic 
performance as an easy screening tool, with sensitivity/specificity at AHI thresholds of 5 and 
30 being 100/75% and 80/100%, respectively, compared with polysomnography (Gan et al, 
2017). Although the reliability of the WatchPAT with Japanese patients has not been reported 
so far, the WatchPAT has attracted attention as an alternative diagnostic tool of OSA and has 
been gradually available in Japanese medical institutions. 
Herein, we investigated the incidence of OSA in Japanese hospitalized patients with T2D 
using the WatchPAT, a portable device enabling simple and accurate OSA testing. We also 
explored the associations between OSA and various clinical characteristics, especially among 
non-obese subjects.  
 
 
Materials and Methods 
Subjects 
This was a cross-sectional prospective study. This study was conducted at Yokohama City 
University Medical Center in Kanagawa Prefecture, Japan. A total of 218 patients with T2D 
aged 18 to 88 years were registered between December 2014 and February 2017. The subjects 
were admitted for the purpose of glycemic control and were fitted with the device overnight in 
the hospital while their glucose levels were stable (at least either fasting blood glucose 90-
120mg/dl or 2-hour postprandial blood glucose 120-180mg/dl) in order to avoid the 
confounding effects of hyperglycemia. The average duration of hospitalization was 12-14 days 
and it took approximately 7-10 days to control hyperglycemia. The patients which participated 
in this study were treated by diet therapy with a determined calorie content, several oral anti-
hyperglycemic agents and/or insulin after admission to control and maintain glycaemia – 
adjusted according to 6 times daily testing by finger-stick monitoring (before every meal and 
2 hours after every meal). There were no additional costs beyond the usual hospitalization fees. 
The exclusion criteria were as follows: 1) a history of severe neuropathy and/or autonomic 
dysfunction, 2) cardiac disease (arrhythmia, presence of a permanent pacemaker, and others), 
3) use of continuous positive airway pressure for OSA, 4) serious diseases other than diabetes 
(advanced malignancy, decompensated liver cirrhosis, and others), 5) use of alpha and/or beta-
adrenergic receptor blockers, 6) chronic insomnia, and 7) pregnancy. Patients previously 
diagnosed with hypertension, myocardial infarction, angina pectoris, cerebrovascular diseases, 
and peripheral vascular disease were included. Of the 218 WatchPAT recordings, two were 
obtained from one patient (0.5%) and technical problems with 17 recordings (7.8%) resulted 
in insufficient data. The remaining 200 subjects (129 men and 71 women) with 200 valid 
WatchPAT recordings were enrolled in this study. The study was carried out in accordance with 
the Declaration of Helsinki and was approved by the ethical committee of Yokohama City 
University. Written informed consent was obtained from each participant. 
 
Epworth Sleepiness Scale 
Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS) (Johns, 1991). 
The total score for eight questions (ranging from 0 to 24) was calculated to assess the tendency 
to fall asleep in a variety of common situations and a score above 10 was regarded as indicating 
excessive sleepiness (Johns, 1991).  
 
Assessment of OSA with the WatchPAT 
Diagnosis of OSA was performed using the WatchPAT portable diagnostic device. The 
WatchPAT is worn as a wrist-watch, with no need for wires or a nasal cannula, and it costs 300 
US dollars. It continuously records five physiological variables during the night: peripheral 
arterial tone (PAT), oxygen saturation, heart rate, motor activity (actigraphy), and body position. 
Changes in PAT are measured continuously in the peripheral arterial bed of the fingertips. Since 
PAT reflects physiological changes in pulsatile arterial volume regulated by sympathetic 
activity, its monitoring allows the WatchPAT to indirectly detect apnea/hypopnea events (Bar 
et al, 2003).  
The frequency of obstructive events was reported as AHI (Jung et al, 2016). The AHI was 
the total number of apnea and hypopnea episodes per hour of sleep. An AHI score ≥5 was 
indicative of OSA. The severity of OSA was assessed by calculating the AHI and was defined 
as follows, according to the American Academy of Sleep Medicine (AASM) guidelines: no 
OSA (AHI<5), mild OSA (AHI 5–15), moderate OSA (AHI 15–30), and severe OSA (AHI≧30) 
(Flemons et al, 1999). Previous studies have shown a significant correlation between the AHI 
recorded by the WatchPAT and the AHI determined by polysomnography (Pearson’s coefficient 
= 0.87 to 0.94, P<0.001) (Gan et al, 2017). With AHI thresholds of 5, 15, and 30, the sensitivity 
and specificity were 95.8–100% and 75–100%, 84.6–93.7% and 73.3–100%, and 80–85.7% 
and 91.7–100%, respectively (Gan et al, 2017). 
 
Laboratory measurements 
The weight and height of each patient were measured, and the BMI was calculated as weight 
in kg divided by height in m2. Obesity was defined as BMI≧25 kg/m2 according to the Asian 
cutoff value of the World Health Organization (WHO Expert Consultation). Diabetes was 
diagnosed according to the Japan Diabetes Society definition, using the results of a 75-g oral 
glucose tolerance test (fasting plasma glucose ≧126 mg/dL or 2 h plasma glucose≧200 mg/dL) 
and hemoglobin A1c (HbA1c) ≧6.5%. Complications of diabetes such as hypertension, 
dyslipidemia, and coronary heart disease were also included in this study. Hypertension was 
defined as a systolic blood pressure≧140 mmHg, diastolic blood pressure≧90 mmHg, or use 
of antihypertensive medication. Dyslipidemia was defined in accordance with the Japan 
Atherosclerosis Society’s guidelines as a low-density lipoprotein cholesterol level (LDL-
C)>140 mg/dL, triglyceride (TG) level>150 mg/dL, high-density lipoprotein cholesterol 
(HDL-C) level<40 mg/dL, and/or use of lipid-lowering medication. Coronary heart disease 
indicated old myocardial infarction, coronary artery bypass graft, and percutaneous coronary 
intervention. Patients who had any of these events before this study were considered to have a 
history of cardiovascular disease. 
The diagnosis of diabetic peripheral neuropathy was evaluated by physicians in charge, using 
a 128-Hz tuning fork and pinprick. Neuropathy was defined as the presence of two of the 
following three findings: symptoms (pain, numbness, itchiness, poor balance), absent 
/decreased Achilles tendon reflex, and loss of vibration perception according to the “diabetic 
peripheral neuropathy diagnostic and treatment recommendations” established by the Japan 
Diabetes Society. Diabetic retinopathy was assessed by an ophthalmologist and classified as 
non-, simple, and proliferative diabetic retinopathy. Diabetic nephropathy was assessed by 
physicians in charge and defined as being present in patients with microalbuminuria (urinary 
albumin excretion 30–300 mg/day), macroalbuminuria (urinary albumin excretion>300 
mg/day and glomerular filtration rate (GFR)≧30 mL/min/1.73m2) or renal insufficiency (GFR 
<30 mL/min/1.73m2) (Wada et al, 2014). 
Venous blood samples were collected after overnight fasting for the measurement of fasting 
glucose, HbA1c, C-peptide immunoreactivity (CPR), serum total cholesterol, TG, HDL-C, and 
LDL-C. Twenty-four-hour urine was also examined for the measurement of urinary albumin 
excretion. 
Statistical analysis 
Data were analyzed using SPSS version 22 (IBM Corp., Armonk, NY) and results are 
expressed as mean (± standard deviation (SD) for normally distributed variables (all except for 
the ESS scores and TG) and as median with interquartile ranges in parentheses for non-
normally distributed variables (ESS scores and TG). The normality of the distribution of 
continuous variables was evaluated using the Kolmogorov-Smirnov test. Categorical data are 
presented as percentages (0–100% range). Comparisons between mean values were performed 
with Student’s t-tests, and median values with the Mann-Whitney U test. Categorical variables 
were assessed by the chi-squared (χ2) test. A multivariate logistic regression model was used 
to estimate odds ratios (ORs), and 95% confidence intervals (CIs) were used to evaluate the 
relationship between OSA and possible risk factors, including age and sex, which have shown 
significant associations to both diabetes and OSA (Partinen, 1995; Levinson et al, 1993). Any 
variable with P value<0.1 on bivariate analysis was also included as a potential confounder in 
a multivariate logistic regression model. A two-tailed P value≦0.05 was considered to indicate 
statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
Results 
OSA in patients with Type 2 diabetes 
There were 129 men (64.5%) (aged 59.6±13.5 years with a BMI of 26.0±4.9 kg/m2) and 71 
women (35.5%) (aged 61.1±13.9 years with a BMI of 26.7±5.7 kg/m2). The age range was 18–
88 years, and 16% of the subjects were aged>75 years. The BMI ranged from 14.3 to 46.7 
kg/m2, with 57% of patients being classified as obese (BMI≧25 kg/m2). The duration of 
diabetes was ≧10 years in 55% of the subjects. Almost all patients (99%) underwent sleep 
monitoring during hospitalization, and glycemic control was poor on admission with a mean 
HbA1c of 9.9%. Among the 200 patients, a total of 161 patients (80.5%, 95% CI: 74.9%–86%) 
were classified as having OSA based on a threshold AHI of 5, including 76.7% of the male 
patients and 87.3% of the female patients. The prevalence of an AHI>5 increased with body 
weight, and OSA was found in 38.9% (7/18), 73.5% (50/68), 86.5% (64/74), and 97.5% (39/40) 
of the patients with a BMI<20, BMI ≥20 and <25, BMI ≥25 and <30, and BMI≥30 kg/m2, 
respectively.  
Figure 1 indicates the prevalence of OSA according to the BMI categories. The prevalence 
of moderate to severe OSA in all patients increased with a BMI≧20 kg/m2. Among the subjects 
with a BMI≥30 kg/m2, approximately 80% had an AHI≥15.  
To assess the prevalence and characteristics of OSA in the patients without obesity, subjects 
with a BMI<25 kg/m2 were divided into two groups according to the diagnosis of OSA (Table 
1). Among the non-obese subjects, patients with OSA had a weight approximately 1.5 kg higher 
than patients without OSA and a BMI of 22.3±2.2 vs. 21.0±2.7 kg/m2 (P<0.05). In addition, 
patients with OSA had higher triglyceride levels than those without OSA (92 vs. 141 mg/dl, 
P=0.003). 
 
Figure 1. Prevalence of obstructive sleep apnea according to the body-mass index (BMI) 
categories. BMI measured in kg/m2 
 
Subjects with OSA (Table 1) were more likely to have slightly worse glycemic control and 
a higher CPR-index, as well as hypertension, dyslipidemia, and coronary vascular disease. 
There was also a tendency for patients with OSA to have shorter sleep duration than those 
without OSA (6.9 vs 6.5, P=0.071). 
No differences in smoking or the sex ratio were observed between the patients with and 
without OSA, and there was also no significant difference in the ESS score between the two 
groups (6 vs 5, P=0.878). 
Regarding the microvascular complications of diabetes, neuropathy tended to be more 
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frequent and nephropathy appeared to be more severe in patients with OSA compared to those 
without OSA.  
Among the 86 non-obese subjects, 69 (80.2%) were using oral hypoglycemic agents and 65 
(75.6%) were using insulin. There was no significant difference in antidiabetic therapy between 
patients with or without OSA, but patients with OSA tended to use more medications for 
diabetes than those without OSA. 
The presence of OSA was associated with serum triglyceride level among non-obese subjects 
in the logistic regression analysis (age, sex, and neuropathy OR: 1.01, 95% CI: 1.00–1.02) 
(P=0.042). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Clinical features of 86 patients with type 2 diabetes and BMI<25 
Characteristics AHI<5 (n=29) AHI≧5 (n=57) P value 
Age, years 64.2±11.1 65.8±11.6 0.525 
Men, % 68.9 64.9 0.707 
Smoker, % 62.1 63.2 0.921 
Alcohol, % 18.6 31.4 0.494 
HbA1c, % 9.9±2.6 10.6±2.3 0.217 
Diabetes duration, years 13.2±12.3 12.6±11.7 0.839 
ESS 6(3-9) 5(3-9) 0.878 
Sleep time, h 6.9±0.8 6.5±1.3 0.071 
REM sleep, % 21.5±6.1 20.1±8.9 0.411 
Body weight, kg 56.6±10.5 58.2±9.3 0.434 
Body Mass Index, kg/m2 21.0±2.7 22.3±2.2 0.028 
FBS, mg/dl 165.7±56.8 162.8±66.1 0.841 
CPR-index 1.1±0.7 1.3±0.8 0.369 
⊿CPR, ng/mL 2.5±2.1 2.2±1.9 0.538 
Hypertension, % 15.1 37.2 0.321 
Cardiovascular disease history, % 10.3 17.5 0.378 
Dyslipidemia, % 17.4 41.9 0.309 
HDL, mg/dL 47.1±14.1 48.4±19.1 0.753 
LDL, mg/dL 99.7±36.5 105.5±38.4 0.5 
TG, mg/dL 92 (75-123) 141.0 (96-193.5) 0.003 
Anti-hyperlipidemia medication, % 11.6 27.9 0.494 
Dyslipidemia + Hypertension, % 10.5 27.9 0.314 
Diabetic complications    
Neuropathy, % 48.3 70.2 0.072 
Retinopathy, % 
NDR 31 36.8 0.789 
SDR 37.9 40.4 0.875 
PDR 24.1 14 0.428 
Nephropathy, % 
Micro 13.8 24.6 0.246 
Macro 6.9 14 0.329 
Renal insufficiency 6.9 10.5 0.584 
Diabetes medication 
One, % 17.2 7 0.388 
Two, % 31 26.3  
Three, % 37.9 43.9  
Four and more, % 13.8 22.8  
Sulfonylureas, % 3.4 3.5 0.988 
Glinides, % 3.5 14.0 0.099 
DPPⅣ inhibitors, % 48.3 56.1 0.489 
Metformin, % 17.2 33.3 0.106 
Thiazolidine, % 3.4 3.5 0.988 
SGLT-2 inhibitors, % 0 5.3 0.112 
α-glucosidase inhibitors, % 44.8 40.4 0.691 
GLP-1 receptor agonists, % 3.5 10.5 0.225 
Basal, u 5.3±4.3 7.0±7.0 0.177 
Bolus, u 8.5±11.0 8.3±12.0 0.945 
Data are presented as %, mean ± standard deviation or median (interquartile range). HbA1c: glycated 
hemoglobin, ESS: Epworth Sleepiness Scale, REM: rapid eye movement, FBS: fasting blood sugar, 
CPR: C-peptide immunoreactivity, CPR-index was calculated using the following formula: CPR-
index=fasting C-peptide immunoreactivity/ fasting blood sugar×100, ⊿CPR=120min C-peptide 
immunoreactivity –fasting C-peptide immunoreactivity, LDL: low-density lipoprotein cholesterol, 
HDL: high-density lipoprotein cholesterol, TG: triglycerides, NDR: no diabetic retinopathy, SDR: 
simple diabetic retinopathy, PDR: proliferative diabetic retinopathy, Micro Nephropathy: 30 to 300mg 
of urinary albumin per day and estimated glomerular filtration rate (eGFR) >30ml/min/1.73m2, Macro 
Nephropathy: more than 300mg of urinary albumin per day and eGFR>30ml/min/1.73m2, Renal 
insufficiency: <30ml/min/1.73m2 
 
 
 
 
 
 
 
 
Discussion 
The present study identified a high prevalence of undiagnosed OSA in Japanese patients with 
T2D, since 80.5% of the patients had OSA. This was higher than reported in previous studies 
of Asian patients with T2D, in which the reported prevalence was 53.9% in Hong Kong (Lam 
et al, 2010), 60% in China (Zhang et al, 2016), 66.7% in Beijing (Zhang et al, 2015), and 77.5% 
and 45.4% in Japan (Kashine et al, 2010; Furukawa et al, 2013). This difference may be due to 
our patients being older. In addition, hospitalized patients for blood glucose level improvement 
were included in the present study, so higher HbA1c values were remarkable. We found that 
the prevalence and severity of OSA increased with BMI among patients with T2D, and 66.3% 
of non-obese patients had OSA along with higher serum triglyceride levels than patients 
without OSA. 
Obesity may be the main contributor to this high prevalence of OSA among the general 
population and patients with T2D. Among obese patients with T2D, a 1-unit increase in BMI 
was significantly correlated with a 10% increase in severe OSA (4). Among our obese patients, 
37.5% had moderate OSA and 40% severe OSA. Similar findings have been obtained in other 
investigations (Foster et al, 2009; Schober et al, 2011).  
To our knowledge, no other studies of OSA among Asians with T2D have assessed its 
prevalence based on obesity status or among normal-weight patients. The prevalence of OSA 
among non-obese subjects in our study (AHI≥15 in 24.4% and AHI≥10 in 33.7%) was similar 
to that previously reported (AHI≥15 in 22.4% and respiratory disturbance index≥10 in 30.8%) 
(Schober et al, 2011; Seicean et al, 2008). Obesity was the major contributor to the higher 
prevalence of OSA among white Europeans in comparison with South Asians (Amin et al, 
2017), whereas other factors may contribute to the development of OSA in Asians, who are 
generally less obese. Undoubtedly, craniofacial differences contribute to the development of 
OSA (Li et al, 2000), but considering the involvement of diabetes, elevation in visceral 
adiposity may be involved. Excess visceral adiposity itself was suggested to be associated with 
increase in OSA in patients with diabetes (Laaban et al, 2009). Furthermore, Asians (BMI<23 
kg/m2) tend to have excess visceral adiposity compared with Caucasians (BMI<25 kg/m2) in a 
similar BMI range (Araneta and Barrett-Connor, 2005), as reported in previous studies with 
non-obese Japanese subjects (Nagaretani et al, 2001). Regarding the lipid profile, the visceral 
fat area was also reported to be associated with serum triglyceride levels in non-obese Japanese 
patients with T2D (Taniguchi et al, 2002), but no other studies have assessed these associations 
with OSA. Further investigations are needed to clarify whether the prevalence of OSA is linked 
to excess visceral fat accumulation and elevation of triglyceride levels independently of obesity. 
Our findings make several contributions to the fields of both OSA and diabetes. An important 
finding was the high prevalence of OSA among non-obese patients, which suggests that 
opportunities for checking OSA and providing subsequent intervention in these patients should 
be increased. Treatment for OSA (e.g., a mouthpiece, continuous positive airway pressure, and 
surgery) should be started at an early stage to prevent complications. In addition, to our 
knowledge, this is the first study on the prevalence of OSA in patients with T2D to be 
performed using the WatchPAT. The 2007 guidelines of the AASM Portable Monitoring Task 
Force recommended use of unattended portable monitoring for the diagnosis of OSA (Collop 
et al, 2007), and this study suggests that convenient devices, such as the WatchPAT, could be 
used to expand screening on a large scale. 
Our study had some limitations. First, focusing on patients with poor glycemic control 
limited the generalizability of the findings. However, as OSA has been associated with higher 
HbA1c values, it is of particular importance for patients with poor glycemic control to undergo 
OSA examination. Second, the WatchPAT was reported to overestimate the AHI score at the 
lower range in an Asian cohort (Gan et al, 2017), which may have affected the prevalence of 
OSA reported in this study. However, another previous study showed a tendency for the 
WatchPAT to underestimate AHI in the mild range (Bar et al, 2003); therefore, whether 
overestimation is peculiar to Asian subjects remains unclear. From the perspective of screening, 
overestimation of OSA can avoid underdiagnosis and improve early detection. Nevertheless, it 
is possible that other types of sleep apnea syndrome might be diagnosed as OSA. Third, the 
WatchPAT may be of limited usefulness in patients under treatment with certain medications 
and with some diseases, as pointed in the exclusion criteria presented in the Materials and 
Methods section. Furthermore, regarding the correlation between polysomnography and 
WatchPAT data, some of the previous studies evaluated relatively small groups; hence, the 
specificity and sensitivity of the WatchPAT and polysomnography need to be compared on a 
larger scale. Additionally, the validity and usefulness of the AHI in OSA research have been 
questioned (Shahar, 2014). Finally, our sample size might have been too small to fully discuss 
the prevalence of OSA in non-obese patients.  
In conclusion, this study found a high prevalence of OSA in Japanese hospitalized patients 
with T2D. In addition, OSA showed a significant relationship with elevation of BMI or the 
triglyceride level in non-obese patients with T2D. In Japan, non-obese T2D patients with poor 
glycemic control should be examined actively using a convenient portable monitor, such as the 
WatchPAT. 
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